The Gene and Virus Therapy Program (GVT) is currently comprised of 22 accomplished members, both basic scientists and clinician investigators from 10 departments and divisions working interactively to create novel gene transfer, virotherapy and immunovirotherapy approaches for the treatment of cancer. This goal is supported by 4 specific aims: 1) To develop novel gene and virus platforms for use in cancer therapy; 2) To develop cancer immunotherapies by exploring the immunomodulatory potential of gene- and virus-based therapeutics; 3) To assess preclinical, clinical, pharmacologic, and immunologic properties of vectors used in cancer therapy and optimize clinical application, and 4) To evaluate the role of cells as carriers in gene and virus therapy approaches to cancer therapy. In addition to intensive intraprogrammatic interactions, substantive interprogrammatic interactions, essential for the process of clinical translation, have been established between the GVT and other Mayo Clinic Cancer Center (MCCC) Programs including the Hematologic Malignancies Program (HMP), the Women's Cancer Program (WCP), the Gastrointestinal Cancer Program (GI), the Neuro- Oncology Program (NONC) and the Cancer Immunology and Immunotherapy Program (CII). The Leader, Dr. Evanthia Galanis, is an oncologist with considerable stature in the field of gene and virus therapy. Productivity of the Program during the current funding period has been significant, including direct funding of $8.9M (vs $7.2M at the 2013 renewal) and a total of 426 publications (as of 12/31/2017). In addition,multiple Phase I/II clinical trials of recombinant viruses or oncolytic virus infected carrier stem cells which were designed, constructed, preclinically tested, and manufactured at the Mayo Clinic have been launched and/or completed under several program sponsored IND. The efficacy observed with some of these approaches has led to later stage, randomized phase II trials. Additionally, there are several promising projects in the translational pipeline, including immunovirotherapy strategies employing virus strains encoding immunostimulatory transgenes such as MV-NAP in breast cancer, vesicular stomatitis virus libraries in melanoma and combinational strategies with immune checkpoint inhibitors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-47
Application #
10113605
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-04-25
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
47
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547

Showing the most recent 10 out of 1129 publications